|
|
| Biotechnology |
 |
|
 |
BSV's
R&D team has focused on developing new generation Recombinant
Therapeutics that replaces the traditional plasma products,
which are in short supply worldwide due to the dependence on
human donors, and runs the risk of viral infections like HIV
etc. The Company's efforts on the Recombinant Therapeutics will
overcome these shortcomings with higher safety and efficacy
profiles and consistent supply. BSV is one of the few companies
globally with in-house expertise to conduct genetic engineering,
process development and scale-up.
|
|
|
Sitemap